




EMLc

ATC codes: J02AA01

Indication	Blastomycosis <span>ICD11 code: 1F22</span>
INN	Amphotericin B
Medicine type	Chemical agent
List type	Core
Formulations	Parenteral > General injections > IV: 50 mg powder for injection in vial (as deoxycholate or liposomal complex)
EML status history	<ul style="list-style-type: none"> <li>First added in 1977 (<a href="#">TRS 615</a>)</li> <li>Changed in 1979 (<a href="#">TRS 641</a>)</li> <li>Changed in 1984 (<a href="#">TRS 722</a>)</li> <li>Changed in 2003 (<a href="#">TRS 920</a>)</li> <li>Changed in 2007 (<a href="#">TRS 950</a>)</li> <li>Changed in 2009 (<a href="#">TRS 958</a>)</li> <li>Changed in 2013 (<a href="#">TRS 985</a>)</li> </ul>
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 
Wikipedia	<a href="#">Amphotericin B</a> 
DrugBank	<a href="#">Amphotericin b</a> 

## Summary of evidence and Expert Committee recommendations

Amphotericin B for the treatment of systemic fungal infections was moved from the complementary to the core list of the EML and EMLc.

